Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research

Francesco Pantano⁴  Maurizio Buscarini²  Sara Boggia³  Andrea Onetti Muda¹  Giuseppe Tonini⁴  Bruno Vincenzi⁴  Michela Amato¹  Giuseppe Perrone¹  Daniele Santini⁴  Francesca Suriano² 

[1] Department of Anatomical Pathology, Campus Bio-Medico, University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy;Department of Urology, Campus Bio-Medico, University of Rome, Via Spilimbergo 10, int 35, 00182 Rome, Italy;Sant’Andrea Hospital, Rome, Italy;Department of Oncology, Campus Bio-Medico, University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy

关键词: Prognosis;    Macrophages polarization;    Tumor-associated macrophages;    Endovescical instillation;    Bladder cancer;   

Others  :  814293
DOI  :  10.1186/1756-9966-32-87

 received in 2013-08-21, accepted in 2013-10-28,  发布年份 2013

【 摘 要 】

Background

To evaluate the prognostic role of TAMs in patients affected by non-muscle invasive bladder cancer (NMIBC), undergone Trans Urethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) therapy.

Methods

Data from 40 patients (36 men, 4 women), mean age 69 years (40-83 years), treated for NMIBC with TURB and BCG instillation were collected. Two different groups were considered: group with and group without bladder cancer recurrence. Correlations between immunofluorescence measured Mtot, M1 and M2 infiltration and clinicopathological parameters were evaluated using Spearman and Mann–Whitney methods. The recurrence-free survival rate was calculated using the Kaplan-Meier method.

Results

CD68 positive cells (Mtot) were observed in all specimens tested. High Mtot, M1 and M2 infiltration was observed in patients with disease recurrence, even before endovescical BCG instillation. Significant value for M2 infiltration (p = 0,042) was found calculating significativity between two group medians before BCG therapy. p = 0,072 and p = 0,180 were observed correlating median of Mtot and M1 between two groups of patients respectively. Values of p = 0,44, p = 0,23 and p = 0,64 from correlation between DFS and Mtot, M1 and M2 median in patients before endovescical BCG instillation, were calculated respectively. Comparing DFS and Mtot, M1 and M2 median in patients group after endovescical BCG instillation significant values were obtained (p = 0,020; p = 0,02; and p = 0,029 respectively).

Conclusions

M2 tumor infiltration could be a prognostic value of recurrence in patients with NMIBC.

【 授权许可】

   
2013 Suriano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
• [2]Fleming JD, Cooper JS, Jenson DE, et al.: AJCC cancer staging manual. 5th edition. 1997.
• [3]Sylvester RJ, van der Meijden AP, Oosterlinck W, et al.: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):465-466.
• [4]Duque JLF, Loughlin KR: An overview of the treatment of superficial bladder cancer. Urol Clin North AM 2000, 1:125-135.
• [5]Chade DC, Borra RC, Nascimento IP, Andrade PM, et al.: Immunomodulatory effects of recombinant BCG ex pressing pertossi toxin on TNF-alfa and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008, 27:78. BioMed Central Full Text
• [6]Morales A, Eidinger D, Bruce AW: Intracavitary bacillus calmette guerin in the treatment of superficial bladder tumors. J Urol 1976, 2:180-183.
• [7]Ayary C, LaRue H, Hovington H, Decobert M, Fradet Y, et al.: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus calmette guerin immunotherapy. Eur Urol 2009, 55(6):1386-1396.
• [8]Bingle L, Brown NJ, Lewis CE: The role of tumor associated macrophages in tumor progression: implications for new anticarncer terapie. J Pathol 2002, 196(3):254-265.
• [9]Andreu P, et al.: FcRy activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
• [10]De Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
• [11]Nardin A, Abastado JP: Macrophages and cancer. Front Biosci 2008, 13:3494-3505.
• [12]Yang XD, et al.: Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b + Ly6G + immature myeloid cells. Nature Med 2011, 17:87-95.
• [13]Sierra JR, et al.: Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008, 205:1673-1685.
• [14]Hanada T, Nakagawa M, Emoto A, et al.: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000, 7:263-269.
• [15]Wei F, Wang H, Huang Q, et al.: Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. J Exp Clin Cancer Res 2013, 32:5. BioMed Central Full Text
• [16]Dufresne M, Dumas G, Asselin E, et al.: Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma. Mol Immunol 2008, 48:1556-1567.
• [17]Song L, Asgharzadeh S, Salo J, et al.: Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 2009, 119(6):1524-1536.
• [18]Jensen TO, Schmidt H, Moller HJ, et al.: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27(20):3330-3337.
• [19]Kurahara H, Shinchi H, Mataki Y, et al.: Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011, 167(2):e211-e219.
• [20]Welsh TJ, Green RH, Richardson D, et al.: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small cell lung cancer. J Clin Oncol 2005, 23(35):8959-8967.
• [21]Wang R, Lu M, Zhang J, Chen H, et al.: Increased IL-10 mRNA expression in tumor associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011, 30:62. BioMed Central Full Text
• [22]Puhakka A, Kinnula V, Napankangas U, et al.: High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS 2003, 111(12):1137-1146.
• [23]Tran TA, Kallakury BV, Ambros RA, et al.: Prognostic significante of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer 1998, 83(2):276-282.
• [24]Binion DG, Fu S, Ramanujam KS, et al.: iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 1998, 275(3 Pt 1):G592-G603.
• [25]Luoma JS, Stralin P, Marklund SL, et al.: Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitome characteristics of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 1998, 18(2):157-167.
• [26]Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
• [27]Cuschieri A, Fayers P, Fielding J, The Surgical Cooperative Group, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Lancet 1996, 347(9007):995-999.
• [28]Ohno S, Inagawa H, Dhar DK, et al.: Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the Impact on FasL-mediated counterattack. Anticancer Res 2005, 25(1B):463-470.
• [29]Moestrup SK, Moller HJ: CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004, 36:347-354.
• [30]Stout RD, Jiang C, Matta B, et al.: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 175:342-349.
• [31]Foukas PG, Tsilivakos V, Zacharatos P, et al.: Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small cell lung carcinomas: a putative mechanism of tumor-induced immunosuppression? Anticancer Res 2001, 21(4A):2609-2615.